Top

Published in:

01-09-2003 | Review

NK cells in allogeneic bone marrow transplantation

Author: Ioannis A. Voutsadakis

Published in: Cancer Immunology, Immunotherapy | Issue 9/2003

Abstract

NK cells, until recently an ignored subset of lymphocytes, have begun to emerge as important cytotoxic effectors. It is now accepted that NK cells together with T cells constitute major actors in graft-versus-leukemia reaction after allogeneic bone marrow transplantation (BMT). Over the last several years the mechanisms regulating the activation of NK cells have been the subject of intense investigations encouraged by the clinical implications that these studies will have. This article provides a general overview of NK-cells biology and regulation pertinent to their function in allogeneic BMT, followed by a review of the in vivo preclinical and clinical evidence for the beneficial effect of NK cells in the adoptive immunotherapy of leukemia.

Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, Murphy WJ (1998) Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin.Invest 101:1835–1842

Ashkar AA, Di Santo JP, Croy BA (2000) Interferon gamma contributes to initiation of uterine vascular modification, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy. J Exp Med 192:259–270CrossRefPubMed

Bakker AB, Wu J, Phillips JH, Lanier LL (2000) NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals. Hum Immunol 61:18–27CrossRefPubMed

Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727–729CrossRefPubMed

Bensussan A (1998) The human natural killer lymphocyte receptors for MHC class I molecules. Eur Cytokine Netw 9:577–583PubMed

BlEry M., Olcese L, Vivier E (2000) Early signaling via inhibitory and activating NK receptors. Hum Immunol 61:51–64PubMed

Bolland S, Ravetch JV (1999) Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol 72:149–177PubMed

Carayol G, Giron-Michel J, Azzarone B, Castagna L, Cambier N, Mishal Z, Bourhis JH, Chouaib S, Caignard A (2000) Altered natural killer cell differentiation in CD34+ progenitors from chronic myeloid leukemia patients. Oncogene 19:2758–2766CrossRefPubMed

Carayol G., Robin C,.Bourhis JH, Bennaceur-Griscelli A, Chouaib S, Coulombel L, Caignard A (1998) NK cells differentiated from bone marrow, cord blood and peripheral blood stem cells exhibit similar phenotype and functions. Eur J Immunol 28:1991–2002PubMed

10.

Champlin RE., Passweg JR, Zhang MJ, Rowlings PA, Pelz CJ, Atkinson KA, Barrett AJ, Cahn JY, Drobyski WR, Gale RP, Goldman JM, Gratwohl A, Gordon-Smith EC, Henslee-Downey PJ, Herzig RH, Klein JP, Marmont AM, O'Reilly RJ, Ringden O, Slavin S, Sobocinski KA, Speck B, Weiner RS, Horowitz MM (2000) T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 95:3996–4003PubMed

11.

Colonna,M., Navarro F, Bellon T, Llano M, Garcia P, Samaridis J, Angman L, Cella M, Lopez-Botet M (1997) A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp.Med 186:1809–1818PubMed

12.

Colonna M, Samaridis J (1995) Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 268:405–408PubMed

13.

Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22:633–640PubMed

14.

Crocker PR, Varki A (2001) Siglecs, sialic acids and innate immunity. Trends Immunol 22:337–342CrossRefPubMed

15.

Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ (2001) ULBPs, novel MHC class I–related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14:123–133PubMed

16.

Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D, Gastaut JA, Pende D, Olive D, Moretta A (2002) Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 99:3661–3667CrossRefPubMed

17.

Dietrich J, Cella M, Colonna M (2001) Ig-like transcript 2 (ILT2)/leukocyte Ig-like receptor 1 (LIR1) inhibits TCR signaling and actin cytoskeleton reorganization. J Immunol 166:2514–2521PubMed

18.

Djeu JY, Jiang K, Wei S (2002) A view to a kill: signals triggering cytotoxicity. Clin Cancer Res 8:636–640PubMed

19.

Dorfman JR, Raulet DH (1998) Acquisition of Ly49 receptor expression by developing natural killer cells. J Exp Med 187:609–618CrossRefPubMed

20.

Drobyski WR, Klein J, Flomenberg N, Pietryga D, Vesole DH, Margolis DA, Keever–Taylor CA (2002) Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. Blood 99:806–814CrossRefPubMed

21.

Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA (2002) Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 100:1935–1947CrossRefPubMed

22.

Fehniger TA, Caligiuri MA (2001) Interleukin 15: biology and relevance to human disease. Blood 97:14–32PubMed

23.

Gumperz JE, Valiante NM, Parham P, Lanier LL, Tyan D (1996) Heterogeneous phenotypes of expression of the NKB1 natural killer cell class I receptor among individuals of different human histocompatibility leukocyte antigens types appear genetically regulated, but not linked to major histocompatibililty complex haplotype. J Exp Med 183:1817–1827PubMed

24.

Held W, Kunz B (1998) An allele-specific, stochastic gene expression process controls the expression of multiple Ly49 family genes and generates a diverse, MHC-specific NK cell receptor repertoire. Eur J Immunol 28:2407–2416

25.

Hessner MJ, Endean DJ, Casper JT, Horowitz MM, Keever–Taylor CA, Roth M, Flomenberg N, Drobyski WR (1995) Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 86:3987–3996PubMed

26.

Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH (2002) The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17:19–29PubMed

27.

Johansson MH, Bieberich C, Jay G, Karre K, Hoglund P (1997) Natural killer cell tolerance in mice with mosaic expression of major histocompatibility complex class I transgene. J Exp Med 186:353–364CrossRefPubMed

28.

Lanier LL (2000) Turning on natural killer cells. J Exp Med 191:1259–1262CrossRefPubMed

29.

Lanier LL, Bakker AB (2000) The ITAM–bearing transmembrane adaptor DAP12 in lymphoid and myeloid cell function. Immunol Today 21:611–614CrossRefPubMed

30.

Leibson PJ (1998) Cytotoxic lymphocyte recognition of HLA-E: utilizing a nonclassical window to peer into classical MHC. Immunity 9:289–294PubMed

31.

Lopez-Botet M, Bellon T (1999) Natural killer cell activation and inhibition by receptors for MHC class I. Curr Opin Immunol 11:301–307PubMed

32.

Love PE, Shores EW (2000) ITAM multiplicity and thymocyte selection: how low can you go? Immunity 12:591–597

33.

Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, Davis DM, Strominger JL, Yewdell JW, Porgador A (2001) Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409:1055–1060CrossRefPubMed

34.

Miller JS (2002) Biology of natural killer cells in cancer and infection. Cancer Invest 20:405–419CrossRefPubMed

35.

Moretta A, Biassoni R, Bottino C, Mingari MC, Moretta L (2000) Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol Today 21:228–234PubMed

36.

Moretta A, Bottino C, Pende D, Tripodi G, Tambussi G, Viale O, Orengo A, Barbaresi M, Merli A, Ciccone E, Moretta L (1990) Identification of four subsets of human CD3−CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J Exp Med 172:1589–1598PubMed

37.

Mrozek E, Anderson P, Caligiuri MA (1996) Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 87:2632–2640PubMed

38.

Nakajima H, Colonna M (2000) 2B4: an NK cell activating receptor with unique specificity and signal transduction mechanism. Hum Immunol 61:39–43PubMed

39.

Parolini S, Bottino C, Falco M, Augugliaro R, Giliani S, Franceschini R, Ochs HD, Wolf H, Bonnefoy JY, Biassoni R, Moretta L, Notarangelo LD, Moretta A (2000) X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med 192:337–346PubMed

40.

Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J, Schrader S, Burkhead S, Heipel M, Brandt C, Kuijper JL, Kramer J, Conklin D, Presnell SR, Berry J, Shiota F, Bort S, Hambly K, Mudri S, Clegg C, Moore M, Grant FJ, Lofton-Day C, Gilbert T, Rayond F, Ching A, Yao L, Smith D, Webster P, Whitmore T, Maurer M, Kaushansky K, Holly RD, Foster D (2000) Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408:57–63

41.

Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L, Marcenaro E, Accame L, Malaspina A, Biassoni R, Bottino C, Moretta L, Moretta A (1999) Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 190:1505–1516CrossRefPubMed

42.

Raulet DH, Held W, Correa I, Dorfman JR, Wu MF, Corral L (1997) Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I–specific Ly49 receptors. Immunol Rev 155:41–52PubMed

43.

Raulet DH, Vance RE, McMahon CW (2001) Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 19:291–330CrossRefPubMed

44.

Roth C, Carlyle JR, Takizawa H, Raulet DH (2000) Clonal acquisition of inhibitory Ly49 receptors on developing NK cells is successively restricted and regulated by stromal class I MHC. Immunity 13:143–153PubMed

45.

Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin RS, Martelli MF, Velardi A (1999) Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94:333–339PubMed

46.

Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097–2100CrossRefPubMed

47.

Salcedo M, Diehl AD, Olsson–Alheim MY, Sundback J, Van Kaer L, Karre K, Ljunggren HG (1997) Altered expression of Ly49 inhibitory receptors on natural killer cells from MHC class I–deficient mice. J Immunol 158:3174–3180PubMed

48.

Sasazuki T, Juji T, Morishima Y, Kinukawa N, Kashiwabara H, Inoko H, Yoshida T, Kimura A, Akaza T, Kamikawaji N, Kodera Y, Takaku F. 1998. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 339:1177–1185

49.

Sivakumar PV, Gunturi A, Salcedo M, Schatzle JD, Lai WC, Kurepa Z, Pitcher L, Seaman MS, Lemonnier FA, Bennett M, Forman J, Kumar V (1999) Cutting edge: expression of functional CD94/NKG2A inhibitory receptors on fetal NK1.1+Ly-49− cells: a possible mechanism of tolerance during NK cell development. J Immunol 162:6976–6980PubMed

50.

Sivori S, Falco M, Marcenaro E, Parolini S, Biassoni R, Bottino C, Moretta L, Moretta A (2002) Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proc Natl Acad Sci USA 99:4526–4531CrossRefPubMed

51.

Sivori S, Vitale M, Morelli L, Sanseverino L, Augugliaro R, Bottino C, Moretta L, Moretta A (1997) p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 186:1129–1136CrossRefPubMed

52.

Valiante NM, Uhrberg M, Shilling HG, Lienert–Weidenbach K, Arnett KL, D'Andrea A, Phillips JH, Lanier LL, Parham P (1997) Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7:739–751PubMed

53.

Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A (1998) NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 187:2065–2072CrossRefPubMed

54.

Vitale M, Falco M, Castriconi R, Parolini S, Zambello R, Semenzato G, Biassoni R, Bottino C, Moretta L, Moretta A (2001) Identification of NKp80, a novel triggering molecule expressed by human NK cells. Eur J Immunol 31:233–242CrossRefPubMed

55.

Vivier E, Tomasello E, Paul P (2002) Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition? Curr Opin Immunol 14:306–311

56.

Voutsadakis IA (2002) Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia. Anticancer Drugs 13:685–692CrossRefPubMed

57.

Witt CS, Dewing C, Sayer DC, Uhrberg M, Parham P, Christiansen FT (1999) Population frequencies and putative haplotypes of the killer cell immunoglobulin-like receptor sequences and evidence for recombination. Transplantation 68:1784–1789PubMed

58.

Wu MF, Raulet DH (1997) Class I deficient hemopoietic cells and nonhemopoietic cells dominantly induce unresponsiveness of natural killer cells to class I–deficient bone marrow cell grafts. J Immunol 158:1628–1633PubMed

59.

Zeis M, Uharek L, Glass B, Steinmann J, Dreger P, Gassmann W, Schmitz N (1997) Allogeneic MHC–mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukaemia effect in mice. Br J Haematol 96:757–761PubMed

Title: NK cells in allogeneic bone marrow transplantation
Author: Ioannis A. Voutsadakis
Publication date: 01-09-2003
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 9/2003
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-003-0378-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2003

Preclinical evaluation of anti-CD86 immunotoxin in rhesus monkeys: analysis of systemic toxicity, pharmacokinetics, and effect on primary T-cell responses

Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer

Life-prolonging effect of immunocell BAK (BRM-activated killer) therapy for advanced solid cancer patients: prognostic significance of serum immunosuppressive acidic protein levels

Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck

Streptococcal preparation OK-432: a new maturation factor of monocyte-derived dendritic cells for clinical use

CD26 expression determines lung metastasis in mutant F344 rats: involvement of NK cell function and soluble CD26

Keynote webinar | Spotlight on antibody–drug conjugates in cancer